Condition: Fibrolamellar Hepatocellular Carcinoma (FLC) · Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
The primary objective of the trial is the safety and tolerability of administering a vaccine targeting the DNAJB1-PRKACA fusion kinase, in combination with nivolumab and ipilimumab in patients with unresectable or metastatic FLC and with non-FLC solid tumors and to assess the T-cell response.
This description comes directly from the study's public registry record.
Colleen Apostol, RN · 410-614-3644 · GIClinicalTrials@jhmi.edu
Marina Baretti, MD · 410-614-1058 · mbarett1@jhu.edu
Always discuss trial participation with your own doctor first.
| Sidney Kimmel Comprehensive Cancer Center | Baltimore, Maryland, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04248569